サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：BCGワクチンの世界市場-2022-2029
市場調査レポート
商品コード
1140729

BCGワクチンの世界市場-2022-2029

Global BCG Vaccine Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 170 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.53円
BCGワクチンの世界市場-2022-2029
出版日: 2022年10月20日
発行: DataM Intelligence
ページ情報: 英文 170 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場力学

新興国および低開発国における結核の有病率の増加が市場成長を牽引

世界各地、特にインド、中国、アフリカなどの発展途上国や低開発国における結核の有病率の増加は、この病気に対する唯一のワクチンであるBCGワクチンの需要に拍車をかけることになるでしょう。世界結核レポート2020によると、結核患者のほとんどはWHO地域の東南アジア（43％）、アフリカ（25％）、西太平洋（18％）で、東地中海（8.3％）、アメリカ（3.0％）、欧州（2.3％）のシェアは小さくなっています。高結核負荷国30カ国は、全世界の推定発症数の86％を占め、そのうちインド（26％）、中国（8.5％）、インドネシア（8.4％）、フィリピン（6.0％）、パキスタン（5.8％）、ナイジェリア（4.6％）、バングラディシュ（3.6％）、南アフリカ（3.3％）と8カ国は世界全体の3分の2を占めています。このような新興国における高い有病率は、予測期間中のBCGワクチン市場を牽引しています。

しかし、BCGワクチンの一部の副作用は、市場の成長に悪影響を及ぼします。個人におけるBCGワクチンの副作用は、予測期間中の世界市場の成長を抑制すると予想される重要な要因です。さらに、新興国におけるBCGワクチンの供給不足も、近い将来、市場全体の成長を妨げると予想される要因のひとつです。米国泌尿器科学会によると、米国で唯一BCGを製造しているメルク・アンド・カンパニーは、世界中でこの製品の使用とニーズが高まっているため、世界的にBCGが不足しているとAUAに通知しています。これに対し、メルク社は2020年まで投与量の不足が続くと見て、BCGの生産量を引き上げました。

地理的浸透度。

予測期間中、アジア太平洋地域が圧倒的なシェアを占めています。

本調査では、地域別に、北米、欧州、アジア太平洋、南米、中東・アフリカなどの世界市場におけるBCGワクチン市場を分析しています。

アジア太平洋地域は、予測期間において世界のBCGワクチン市場で大きな市場シェアを占めています。予測期間中、アジアではインドがかなりの成長を示すと予想されます。インドでは、2021年の全年齢の全形態の結核の有病率は人口1人当たり312人で、全形態の有病率が最も高いのはデリーの人口1人当たり747人、最も低いのはグジャラート州の人口1人当たり137人でした。

さらに、中東とアフリカは予測期間中に金額で大きな成長を示すと予想されます。アジア太平洋地域のBCGワクチン市場は、同地域における結核患者の増加や、結核対策に向けた政府の取り組みの増加を背景に、予測期間中に急成長が見込まれています。

競合情勢。

BCGワクチン市場は、ワクチン生産における大規模な開発の存在により、非常に競争が激しい市場です。世界市場の成長に貢献している主なBCGワクチンメーカーには、Merck &Co., Inc.、Sanofi Pasteur、日本BCG研究所、中国生物医薬集団（中国国家薬品集団公司の子会社）、インド血清研究所、InterVax Ltd.、GreenSignal Bio Pharma Limited（GSBPL）およびStatens Serum Instituteなどが挙げられます。大手企業は、BCGワクチン市場の世界の成長のために新製品の上市や拡大戦略を採用しています。2021年1月、Merk社はTice BCGの製造能力を拡大するため、米国に新施設を建設しました。2020年7月、セラム研究所はBCGワクチンの第3相臨床試験を実施。インド血清研究所は、BCGワクチン候補のVPM1002について、高齢者の高リスク者におけるCOVID-19の感染および重症化転帰を低減する能力を評価するための第3相臨床試験を実施しています。2020年9月、インド血清研究所とビル＆メリンダ・ゲイツ財団は、1億回分のCOVID-19ワクチンを低・中所得国へ提供するために協力しました。このコラボレーションは、Serum Institute of Indiaに製造能力増強のための先行資本を提供しました。この協力は、COVID-19ワクチンの開発を促進し、迅速かつ世界のアクセスを確保するために大きく役立っています。

COVID-19の影響世界のBCGワクチン市場へのネガティブな影響。

COVID-19の発生は、世界のBCGワクチン市場の成長にマイナスの影響を及ぼしています。サプライチェーンの混乱は、パンデミックの中で市場の成長に大きな影響を与えました。COVID-19ワクチン開発への重点的な取り組みがエスカレートしたことで、BCGワクチンがデスケーリングされるようになりました。したがって、COVID-19のパンデミックは、2020年のBCGワクチン市場の市場価値を阻害しています。

世界のBCGワクチン市場レポートでは、約55の市場データ表、49の図、170ページの構成で提供しています

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

  • 製品別市場内訳
  • 人口統計別市場内訳
  • アプリケーション別市場内訳
  • 地域別市場内訳

第4章 市場力学

  • 市場影響要因
    • 促進要因
      • 発展途上国および低開発国における結核の有病率の上昇
      • 世界の出生率の上昇
    • 抑制要因
      • BCGワクチンの副作用
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • バリューチェーン分析
  • PEST分析
  • プライシング分析
  • 法規制分析
  • 保険償還分析
  • アンメットニーズ
  • 特許動向

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、あるいは将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的な取り組み
  • まとめ

第7章 製品別

  • 免疫系BCG
  • 治療用BCG

第8章 人口統計別

  • 小児科（0-18歳）
  • 成人（19～35歳）

第9章 アプリケーション別

  • 病院
  • 診療所

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A（合併・買収）分析

第12章 企業プロファイル

  • Merck & Co.
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Sanofi Pasteur
  • Japan BCG Laboratory
  • China National Biotech Group
  • Serum Institute of India Pvt. Ltd
  • InterVax Ltd
  • GREENSIGNAL BIO PHARMA LIMITED（GSBPL）
  • STATENS SERUM INSTITUTE
  • Other companies（List Not Exhaustive）

第13章 重要考察

第14章 DataM

目次
Product Code: DMHCIT3107

Market Overview

BCG Vaccine Market was valued at USD YY million in 2021. It is forecasted to reach USD YY million by 2029, growing at a highCAGR during the forecast period (2022-2029).

The only vaccine available to combat Tuberculosis is the Bacillus Calmette-Gurin (BCG) vaccine (TB). One dose is recommended for healthy babies near the time of birth in countries with a high incidence of Tuberculosis. However, only infants at high risk are usually immunized in areas where Tuberculosis is rare, while confirmed cases of Tuberculosis are personally screened and administered. It is also possible to immunize individuals who are not afflicted with Tuberculosis and who have not been recently immunized yet are also susceptible to drug-resistant Tuberculosis. The major factors propelling the growth of the BCG vaccine market are Increases in tuberculosis prevalence, especially in developing and underdeveloped countries, as well as technical developments in the field of vaccine research. Also, the rising birth rates across the globe, especially in China and India, contribute to the market's significant growth. Also, the rise in government policies and a global emphasis on immunization programs further drive demand growth. It is expected that untapped business opportunities in emerging regions can have multiple market growth prospects.

Market Dynamics: Increasing prevalence of Tuberculosis in developing and under-developed countries drives market growth

The increasing prevalence of Tuberculosis across the globe, especially in developing and under-developed countries such as India, China, and Africa, will stir the demand for the BCG vaccine as it is the only vaccine available for the disease. As per the global TB report 2020, most TB cases were in the WHO regions of South-East Asia (43%), Africa (25%) and the Western Pacific (18%), with smaller shares in the Eastern Mediterranean (8.3%), the Americas (3.0%) and Europe (2.3%). The 30 high TB burden countries accounted for 86% of all estimated incident cases worldwide, and eight of these countries accounted for two-thirds of the global total: India (26%), China (8.5%), Indonesia (8.4%), the Philippines (6.0%), Pakistan (5.8%), Nigeria (4.6%), Bangladesh (3.6%) and South Africa (3.3%). This high prevalence in emerging countries drives the market for BCG vaccines during the forecast period.

However, some side effects of the BCG vaccine adversely affect market growth. The side effects of the BCG vaccine among individuals are a key factor expected to curtail the global market's growth over the forecast period. Moreover, the shortage of supply in BCG vaccines in emerging countries is another factor expected to hinder the total market's growth in the near future. According to the American Urology Association, Merk and Company is the only producer of BCG in the United States informed the AUA that they were experiencing a global shortage of BCG due to the growing use and need for this product around the world. In comparison, Merck has raised the production of BCG as they expected the shortage of doses to carry through 2020.

Market Segmentation: The Immune BCG segment will project the fastest growth in the market throughout the forecast period

Based on the product, the BCG vaccine market has been classified into Immune BCG and Therapy BCG.

Immune BCG dominated the global market in 2021. Also, the Immune BCG is expected to present considerable growth shortly. BCG Vaccine is administered to newborns in the risk zone areas with a single dose of Immune BCG to prevent TB development. Therefore, the increasing usage of Immune BCG in the prevention of the development of TB is expected to propel segmental growth shortly.

BCG Vaccine is segmented on the basis of demographics, which includes Pediatrics (0-18 Years), Adults (19-35 Years).

The pediatrics (0-18 Years) segment held a significant market share in the forecast period. Pediatrics (0-18 Years) held the dominant position in the global market during the forecast period. In countries where the BCG vaccine is part of the national childhood immunization policy, BCG is normally offered to all children up to one year of age. In addition, older children (over 1 year of age) who have an elevated chance of contracting Tuberculosis should also be given this vaccine. It is rarely administered above 16 years of age and is never administered above 35 years of age since vaccines are only successful when administered at an early stage of life. It supports segment growth during the forecast period.

BCG Vaccine is segmented on the basis of Application, which includes Hospitals, Clinics, Others.

The hospital's segment held a significant market share in the forecast period. The administration of BCG vaccines done after the birth of a baby in the hospitals supports the segment growth during the forecast period. Moreover, the Clinics are expected to project a considerable CAGR during the forecast period. Older children (more than 1 year of age) who have an elevated risk of contracting Tuberculosis may also receive this vaccine administered at Clinics.

Geographical Penetration: Asia Pacific is the dominating region during the forecast period.

Based on geography, the study analyzes the BCG vaccine market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

Asia Pacific region held a significant market share in the global BCG vaccine market in the forecast period. India is expected to represent considerable growth in Asia during the forecast period. In India, the prevalence of all forms of TB for all ages in India was 312 per lakh population in 2021, the highest prevalence for all forms of TB was 747 per lakh in Delhi, and the lowest was 137 per lakh population in Gujarat.

Moreover, the Middle East and Africa are expected to represent significant growth in value during the forecast period. BCG Vaccine market for the Asia Pacific is expected to observe rapid growth over the forecast period, backed by the growth of tuberculosis cases in the region coupled with increasing government initiatives to combat the disease.

Competitive Landscape:

The BCG vaccine market is highly competitive, owing to the presence of major developments in vaccine production. The key BCG Vaccine players which are contributing to the growth of the global market include Merck & Co., Inc., Sanofi Pasteur, Japan BCG Laboratory, China National Biotech Group (a subsidiary of China National Pharmaceutical Group Corporation), Serum Institute of India Pvt. Ltd., InterVax Ltd., GreenSignal Bio Pharma Limited (GSBPL), and Statens Serum Institute among others. The major players are adopting new product launches and expansion strategies for global growth in the BCG Vaccine market. In January 2021, Merk constructed a new facility in the United States to expand manufacturing capacity for Tice BCG. In July 2020, the Serum institute conducted a phase 3 clinical trial for the BCG vaccine. The Serum Institute of India is conducting a phase III clinical trial of BCG vaccine candidate VPM1002 to evaluate its ability to reduce infection and severe disease outcomes of COVID-19 among high-risk persons of advanced age. In September 2020, the Serum Institute of India and Bill & Melinda Gates Foundation collaborated to make 100 million doses of COVID-19 vaccine available to low and middle-income countries. This collaboration provided upfront capital to Serum Institute of India to increase its manufacturing capacity. This collaboration majorly helps to boost the development of COVID-19 vaccines and ensure rapid, global access to them.

COVID-19 Impact: Negative impact on the global BCG vaccine market.

The outbreak of COVID-19 has negatively impacted the growth of the BCG vaccine market globally. The disruption in the supply chain has majorly impacted the growth of the market amidst the pandemic. The escalated focus on COVID-19 vaccine development has led to de-escalation in BCG vaccines. Therefore, the COVID-19 pandemic has hampered the market value of the BCG Vaccine market in 2020.

The global BCG vaccine market report would provide an access to approximately 55 market data tables, 49 figures and 170 pages

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Product
  • 3.2. Market Snippet by Demographics
  • 3.3. Market Snippet by Application
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Prevalence of Tuberculosis in Developing and under-developed countries
      • 4.1.1.2. Increasing birth rates across the globe
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects of BCG vaccine
    • 4.1.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Value Chain Analysis
  • 5.4. PEST Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs
  • 5.9. Patent Trends

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Segment
  • 7.3. Market Attractiveness Index, By Product Segment
    • 7.3.1. Immune BCG*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Therapy BCG

8. By Demographics

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Demographics Segment
  • 8.3. Market Attractiveness Index, By Demographics Segment
    • 8.3.1. Pediatrics (0-18 Years)*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Adults (19-35 Years)

9. By Application

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
  • 9.3. Market Attractiveness Index, By Application Segment
    • 9.3.1. Hospitals*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Clinics

10. By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Demographics
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. U.S.
      • 10.4.6.2. Canada
      • 10.4.6.3. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Demographics
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. Germany
      • 10.5.6.2. U.K.
      • 10.5.6.3. France
      • 10.5.6.4. Italy
      • 10.5.6.5. Spain
      • 10.5.6.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Demographics
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.6.1. Brazil
      • 10.6.6.2. Argentina
      • 10.6.6.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Demographics
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.6.1. China
      • 10.7.6.2. India
      • 10.7.6.3. Japan
      • 10.7.6.4. Australia
      • 10.7.6.5. Rest of Asia Pacific
  • 10.8. Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Demographics
    • 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Merck & Co.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Sanofi Pasteur
  • 12.3. Japan BCG Laboratory
  • 12.4. China National Biotech Group
  • 12.5. Serum Institute of India Pvt. Ltd
  • 12.6. InterVax Ltd
  • 12.7. GREENSIGNAL BIO PHARMA LIMITED (GSBPL)
  • 12.8. STATENS SERUM INSTITUTE
  • 12.9. Other companies (List Not Exhaustive)

13. Premium Insights

14. DataM Intelligence Analysis

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us